Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal tumor monitoring after prior deferitazole exposure in transfusional iron overload
2014-005086-70Phase 2Terminated
- Sponsor
- Takeda
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferitazole in transfusional hemosiderosis and hemochromatosis (HH), sponsored by Takeda. Primary endpoint: Potential development of renal tumors. Started Jan 2021; status: terminated.
02
Drugs
deferitazole
03
Conditions
transfusional hemosiderosishemochromatosis (HH)
Beyond the preview
Go deeper on 2014-005086-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005086-70.